Amicus Therapeutics Inc (NASDAQ:FOLD)

Add to Watch List

Set Alert

3.40 Data as of May 24	-0.02 / -0.58% Today’s Change	2.47 Today\|\|\|52-Week Range 6.89	+26.87% Year-to-Date

3.40

Data as of May 24

-0.02 / -0.58%

Today’s Change

2.47

Today|||52-Week Range

6.89

+26.87%

Year-to-Date

SECTOR

Health Technology

INDUSTRY

Biotechnology

MARKET CAP

$168.7M

Company Description

Amicus Therapeutics, Inc. is a biopharmaceutical company focuses on the discovery, development and commercialization of orally administered, small molecule drugs known as pharmacological chaperones for the treatment of rare diseases, pharmacological chaperones are a novel, first-in-class approach to treating a broad range of diseases, including lysosomal storage disorders and diseases of neurodegeneration. Amicus develops pharmacological chaperones oral therapies that bind to and stabilize the affected proteins, restoring their shape, proper trafficking, and biological activity. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ.

Contact Information

Amicus Therapeutics, Inc.

1 Cedar Brook Drive

Cranbury New Jersey 08512

P:(609) 662-2000

Investor Relations:
(609) 662-5044

www.amicustherapeutics.com

Employees

Shareholders

Individual stakeholders	48.91%
Other institutional	31.38%
Mutual fund holders	17.70%

Top Executives

John F. Crowley, MBA	Chairman, President & Chief Executive Officer
William D. Baird, III, MBA	Chief Financial Officer
Enrique Dilone, PhD	Vice President-Technical Operations
David J. Lockhart, PhD	Chief Scientific Officer
Robert E. Winkler, MD	Vice President-Clinical Research & Operations

To view my watchlist

Not a member yet?

jobs by

Search for jobs

Search All Jobs from Across the Web

About CNNMoney
Content
Magazines
Site Tools
Stay Connected
- My Account
- Mobile Site & Apps
- Facebook
- Twitter
- LinkedIn
- YouTube
- RSS Feeds
- Newsletters
- Tumblr
- Google+

Market indexes are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer LIBOR Warning: Neither BBA Enterprises Limited, nor the BBA LIBOR Contributor Banks, nor Reuters, can be held liable for any irregularity or inaccuracy of BBA LIBOR. Disclaimer. Morningstar: © 2013 Morningstar, Inc. All Rights Reserved. Disclaimer The Dow Jones Indexes^SM are proprietary to and distributed by Dow Jones & Company, Inc. and have been licensed for use. All content of the Dow Jones Indexes^SM © 2013 is proprietary to Dow Jones & Company, Inc. Chicago Mercantile Association. The market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. FactSet Research Systems Inc. 2013. All rights reserved. Most stock quote data provided by BATS.